KYKOF - Twist Bioscience and Kyowa Kirin team up for GPCR antibody discovery

Twist Bioscience ([[TWST]] -0.4%) has signed a partnership agreement with Kyowa Kirin Pharmaceutical Research, a subsidiary of Kyowa Kirin ([[KYKOF]]) to discover novel antibodies for therapeutic use against an undisclosed G protein-coupled receptor ((GPCR)) target molecule.Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will leverage its biologics and proprietary discovery capabilities to find novel GPCR target specific antibodies for Kyowa Kirin.Twist received an upfront payment upon signing and Kyowa Kirin retains an option to obtain development and commercial rights to any antibodies resulting from the agreement."Kyowa Kirin specializes in leveraging antibody engineering to develop innovative, life-changing medicines. That expertise complements Twist’s unique approach to efficient and robust antibody discovery and optimization," Twist CEO Emily Leproust said.

For further details see:

Twist Bioscience and Kyowa Kirin team up for GPCR antibody discovery